Gritstone bio (GRTS) Stock Forecast, Price Target & Predictions
GRTS Stock Forecast
Gritstone bio stock forecast is as follows: an average price target of $4.67 (represents a 733.63% upside from GRTS’s last price of $0.56) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
GRTS Price Target
The average price target for Gritstone bio (GRTS) is $4.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $3.00. This represents a potential 733.63% upside from GRTS's last price of $0.56.
GRTS Analyst Ratings
According to 5 Wall Street analysts, Gritstone bio's rating consensus is 'Buy'. The analyst rating breakdown for GRTS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Gritstone bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 02, 2024 | Kaveri Pohlman | BTIG | $3.00 | $1.20 | 150.00% | 435.52% |
| Apr 02, 2024 | Roy Buchanan | JMP Securities | $5.00 | $2.35 | 112.77% | 792.54% |
| Oct 30, 2022 | Edward Tenthoff | Piper Sandler | $6.00 | $2.71 | 121.40% | 971.05% |
The latest Gritstone bio stock forecast, released on Apr 02, 2024 by Kaveri Pohlman from BTIG, set a price target of $3.00, which represents a 150.00% increase from the stock price at the time of the forecast ($1.20), and a 435.52% increase from GRTS last price ($0.56).
Gritstone bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $4.00 |
| Last Closing Price | $0.56 | $0.56 | $0.56 |
| Upside/Downside | -100.00% | -100.00% | 614.03% |
In the current month, the average price target of Gritstone bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gritstone bio's last price of $0.56. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 05, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Aug 05, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 14, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 24, 2024 | B. Riley | Buy | Buy | Hold |
| May 13, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 13, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Apr 02, 2024 | BTIG | Buy | Buy | Hold |
| Apr 02, 2024 | JMP Securities | Outperform | Outperform | Hold |
Gritstone bio's last stock rating was published by Cowen & Co. on Aug 14, 2024. The company gave GRTS a "Buy" rating, the same as its previous rate.
Gritstone bio Financial Forecast
Gritstone bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $13.84M | - | $1.96M | $542.00K | $1.33M | $436.00K | - | $4.75M | $3.06M | $2.61M | $2.84M | $39.69M | $1.35M | $939.00K | $488.00K | $1.26M | $884.00K | $984.00K | $1.15M | $1.35M | $96.00K |
| Avg Forecast | $900.00K | $900.00K | $850.00K | $850.00K | $2.53M | $2.59M | $1.72M | $2.85M | $5.11M | $1.89M | $2.51M | $3.17M | $2.91M | $3.61M | $3.19M | $4.21M | $2.86M | $2.24M | $2.24M | $12.21M | $1.23M | $1.19M | $1.53M | $1.25M | $1.10M | $1.13M | $1.10M | $798.50K | $869.49K |
| High Forecast | $900.00K | $900.00K | $850.00K | $850.00K | $2.53M | $3.38M | $1.72M | $2.85M | $11.17M | $1.89M | $2.51M | $3.17M | $2.91M | $3.61M | $3.19M | $4.21M | $2.86M | $2.24M | $2.24M | $12.21M | $1.23M | $1.19M | $1.53M | $1.25M | $1.10M | $1.13M | $1.10M | $798.50K | $1.04M |
| Low Forecast | $900.00K | $900.00K | $850.00K | $850.00K | $2.53M | $1.79M | $1.72M | $2.85M | $1.28M | $1.89M | $2.51M | $3.17M | $2.91M | $3.61M | $3.19M | $4.21M | $2.86M | $2.24M | $2.24M | $12.21M | $1.23M | $1.19M | $1.53M | $1.25M | $1.10M | $1.13M | $1.10M | $798.50K | $695.59K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | 2.71% | - | 0.78% | 0.17% | 0.46% | 0.12% | - | 1.13% | 1.07% | 1.17% | 1.27% | 3.25% | 1.10% | 0.79% | 0.32% | 1.01% | 0.80% | 0.87% | 1.05% | 1.69% | 0.11% |
Gritstone bio's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.85M, with a low forecast of $2.85M, and a high forecast of $2.85M. GRTS's average Quarter revenue forecast represents a -79.38% decrease compared to the company's last Quarter revenue of $13.84M (Dec 23).
Gritstone bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | $-40.24M | - | $-35.73M | $-33.14M | $-28.82M | $-27.74M | - | $-27.37M | $-28.20M | $-26.53M | $-23.52M | $9.52M | $-25.47M | $-24.40M | $-24.22M | $-24.58M | $-26.26M | $-26.38M | $-20.08M | $-16.97M | $-17.59M |
| Avg Forecast | $-900.00K | $-900.00K | $-850.00K | $-850.00K | $-2.53M | $-2.59M | $-1.72M | $-2.85M | $-5.11M | $-1.89M | $-2.51M | $-3.17M | $-2.91M | $-39.66M | $-3.19M | $-29.49M | $-2.86M | $-31.35M | $-32.40M | $-12.21M | $-1.23M | $-22.49M | $-25.54M | $-25.25M | $-1.10M | $-21.51M | $-19.75M | $-17.76M | $-159.27M |
| High Forecast | $-900.00K | $-900.00K | $-850.00K | $-850.00K | $-2.53M | $-1.79M | $-1.72M | $-2.85M | $-1.28M | $-1.89M | $-2.51M | $-3.17M | $-2.91M | $-31.73M | $-3.19M | $-23.59M | $-2.86M | $-25.08M | $-25.92M | $-12.21M | $-1.23M | $-17.99M | $-20.44M | $-20.20M | $-1.10M | $-17.20M | $-15.80M | $-14.21M | $-127.42M |
| Low Forecast | $-900.00K | $-900.00K | $-850.00K | $-850.00K | $-2.53M | $-3.38M | $-1.72M | $-2.85M | $-11.17M | $-1.89M | $-2.51M | $-3.17M | $-2.91M | $-47.59M | $-3.19M | $-35.39M | $-2.86M | $-37.62M | $-38.87M | $-12.21M | $-1.23M | $-26.99M | $-30.65M | $-30.30M | $-1.10M | $-25.81M | $-23.70M | $-21.31M | $-191.12M |
| Surprise % | - | - | - | - | - | - | - | - | 7.88% | - | 14.21% | 10.46% | 9.90% | 0.70% | - | 0.93% | 9.85% | 0.85% | 0.73% | -0.78% | 20.80% | 1.08% | 0.95% | 0.97% | 23.87% | 1.23% | 1.02% | 0.96% | 0.11% |
2 analysts predict GRTS's average Quarter EBITDA for Jun 21 to be $-32.40M, with a high of $-25.92M and a low of $-38.87M. This is -440.36% lower than Gritstone bio's previous annual EBITDA (Mar 21) of $9.52M.
Gritstone bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 | 12 |
| Net Income | - | - | - | - | - | - | - | - | $-30.81M | - | $-35.26M | $-33.99M | $-30.66M | $-30.05M | - | $-28.82M | $-29.77M | $-28.12M | $-25.12M | $7.92M | $-27.17M | $-26.07M | $-25.87M | $-26.21M | $-27.70M | $-27.55M | $-21.17M | $-18.01M | $-18.59M |
| Avg Forecast | $-30.81M | $-28.66M | $-27.94M | $-27.94M | $-27.43M | $-27.43M | $-39.30M | $-45.68M | $-46.88M | $-48.78M | $-49.68M | $-49.50M | $-49.29M | $-42.04M | $-46.83M | $-31.26M | $-37.35M | $-33.23M | $-34.60M | $16.09M | $-59.86M | $-24.04M | $-27.29M | $-26.92M | $-69.56M | $-22.46M | $-20.83M | $-18.84M | $-168.35M |
| High Forecast | $-30.81M | $-28.66M | $-27.94M | $-27.94M | $-27.43M | $-20.21M | $-39.30M | $-45.68M | $-41.67M | $-48.78M | $-49.68M | $-49.50M | $-49.29M | $-33.63M | $-46.83M | $-25.01M | $-37.35M | $-26.58M | $-27.68M | $19.31M | $-59.86M | $-19.23M | $-21.83M | $-21.54M | $-69.56M | $-17.97M | $-16.66M | $-15.07M | $-134.68M |
| Low Forecast | $-30.81M | $-28.66M | $-27.94M | $-27.94M | $-27.43M | $-33.21M | $-39.30M | $-45.68M | $-54.69M | $-48.78M | $-49.68M | $-49.50M | $-49.29M | $-50.44M | $-46.83M | $-37.51M | $-37.35M | $-39.88M | $-41.52M | $12.87M | $-59.86M | $-28.84M | $-32.74M | $-32.31M | $-69.56M | $-26.95M | $-25.00M | $-22.61M | $-202.03M |
| Surprise % | - | - | - | - | - | - | - | - | 0.66% | - | 0.71% | 0.69% | 0.62% | 0.71% | - | 0.92% | 0.80% | 0.85% | 0.73% | 0.49% | 0.45% | 1.08% | 0.95% | 0.97% | 0.40% | 1.23% | 1.02% | 0.96% | 0.11% |
Gritstone bio's average Quarter net income forecast for Jun 21 is $-34.60M, with a range of $-41.52M to $-27.68M. GRTS's average Quarter net income forecast represents a -536.66% decrease compared to the company's last Quarter net income of $7.92M (Mar 21).
Gritstone bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 | 12 |
| SG&A | - | - | - | - | - | - | - | - | $7.92M | - | $6.72M | $6.75M | $6.76M | $6.46M | - | $7.96M | $6.68M | $6.37M | $5.94M | $6.94M | $5.66M | $5.03M | $5.25M | $5.46M | $5.62M | $4.58M | $4.83M | $4.38M | $3.09M |
| Avg Forecast | $5.28M | $5.28M | $4.99M | $4.99M | $14.86M | $15.20M | $10.10M | $16.75M | $29.99M | $11.12M | $14.76M | $18.59M | $17.08M | $21.18M | $18.74M | $24.73M | $16.80M | $13.14M | $13.14M | $71.69M | $7.19M | $6.97M | $8.99M | $7.36M | $6.46M | $6.65M | $6.46M | $4.69M | $5.10M |
| High Forecast | $5.28M | $5.28M | $4.99M | $4.99M | $14.86M | $19.87M | $10.10M | $16.75M | $65.60M | $11.12M | $14.76M | $18.59M | $17.08M | $21.18M | $18.74M | $24.73M | $16.80M | $13.14M | $13.14M | $71.69M | $7.19M | $6.97M | $8.99M | $7.36M | $6.46M | $6.65M | $6.46M | $4.69M | $6.13M |
| Low Forecast | $5.28M | $5.28M | $4.99M | $4.99M | $14.86M | $10.51M | $10.10M | $16.75M | $7.50M | $11.12M | $14.76M | $18.59M | $17.08M | $21.18M | $18.74M | $24.73M | $16.80M | $13.14M | $13.14M | $71.69M | $7.19M | $6.97M | $8.99M | $7.36M | $6.46M | $6.65M | $6.46M | $4.69M | $4.08M |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | - | 0.46% | 0.36% | 0.40% | 0.31% | - | 0.32% | 0.40% | 0.49% | 0.45% | 0.10% | 0.79% | 0.72% | 0.58% | 0.74% | 0.87% | 0.69% | 0.75% | 0.93% | 0.60% |
Gritstone bio's average Quarter SG&A projection for Mar 24 is $16.75M, based on 4 Wall Street analysts, with a range of $16.75M to $16.75M. The forecast indicates a 111.63% rise compared to GRTS last annual SG&A of $7.92M (Dec 23).
Gritstone bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 | 12 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | - | $-0.00 | $-0.30 | $-0.34 | $-0.35 | - | $-0.33 | $-0.38 | $-0.36 | $-0.33 | $0.10 | $-0.72 | $-0.69 | $-0.69 | $-0.71 | $-0.75 | $-0.77 | $-0.63 | $-0.62 | $-7.60 |
| Avg Forecast | $-0.21 | $-0.20 | $-0.20 | $-0.20 | $-0.19 | $-0.19 | $-0.27 | $-0.32 | $-0.33 | $-0.34 | $-0.35 | $-0.35 | $-0.34 | $-0.40 | $-0.40 | $-0.37 | $-0.38 | $-0.52 | $-0.58 | $-0.39 | $-0.61 | $-0.64 | $-0.72 | $-0.73 | $-0.71 | $-0.66 | $-0.62 | $-0.65 | $-5.71 |
| High Forecast | $-0.21 | $-0.20 | $-0.20 | $-0.20 | $-0.19 | $-0.14 | $-0.27 | $-0.32 | $-0.29 | $-0.34 | $-0.35 | $-0.35 | $-0.34 | $-0.40 | $-0.40 | $-0.37 | $-0.38 | $-0.52 | $-0.58 | $-0.39 | $-0.61 | $-0.64 | $-0.72 | $-0.73 | $-0.71 | $-0.66 | $-0.62 | $-0.65 | $-4.56 |
| Low Forecast | $-0.21 | $-0.20 | $-0.20 | $-0.20 | $-0.19 | $-0.23 | $-0.27 | $-0.32 | $-0.38 | $-0.34 | $-0.35 | $-0.35 | $-0.34 | $-0.40 | $-0.40 | $-0.37 | $-0.38 | $-0.52 | $-0.58 | $-0.39 | $-0.61 | $-0.64 | $-0.72 | $-0.73 | $-0.71 | $-0.66 | $-0.62 | $-0.65 | $-6.85 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | - | 0.00% | 0.87% | 0.99% | 0.88% | - | 0.90% | 0.99% | 0.69% | 0.57% | -0.26% | 1.17% | 1.07% | 0.96% | 0.97% | 1.06% | 1.16% | 1.02% | 0.95% | 1.33% |
According to 2 Wall Street analysts, Gritstone bio's projected average Quarter EPS for Jun 21 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -678.68% decrease compared to GRTS previous annual EPS of $0.10 (Mar 21).
Gritstone bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| SGMO | Sangamo Therapeutics | $0.83 | $12.00 | 1345.78% | Hold |
| ALLO | Allogene Therapeutics | $2.88 | $29.00 | 906.94% | Buy |
| GRTS | Gritstone bio | $0.56 | $4.67 | 733.93% | Buy |
| PASG | Passage Bio | $0.73 | $6.00 | 721.92% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| IFRX | InflaRx | $1.44 | $6.00 | 316.67% | Strong Buy |
| HRTX | Heron Therapeutics | $1.90 | $7.00 | 268.42% | Buy |
| FULC | Fulcrum Therapeutics | $3.49 | $9.86 | 182.52% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.05 | $2.83 | 169.52% | Buy |
| ANVS | Annovis Bio | $8.74 | $23.50 | 168.88% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| ANNX | Annexon | $6.99 | $14.00 | 100.29% | Buy |
| LPTX | Leap Therapeutics | $2.80 | $5.50 | 96.43% | Buy |
| AFMD | Affimed | $4.07 | $7.50 | 84.28% | Buy |
| CCCC | C4 Therapeutics | $6.46 | $11.33 | 75.39% | Hold |
| BBIO | BridgeBio Pharma | $26.73 | $44.90 | 67.98% | Buy |
| AUPH | Aurinia Pharmaceuticals | $7.14 | $10.75 | 50.56% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.50 | $7.00 | 27.27% | Buy |
| GTHX | G1 Therapeutics | $7.15 | $4.50 | -37.06% | Buy |
GRTS Forecast FAQ
Is Gritstone bio a good buy?
Yes, according to 5 Wall Street analysts, Gritstone bio (GRTS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of GRTS's total ratings.
What is GRTS's price target?
Gritstone bio (GRTS) average price target is $4.67 with a range of $3 to $6, implying a 733.63% from its last price of $0.56. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Gritstone bio stock go up soon?
According to Wall Street analysts' prediction for GRTS stock, the company can go up by 733.63% (from the last price of $0.56 to the average price target of $4.67), up by 971.05% based on the highest stock price target, and up by 435.52% based on the lowest stock price target.
Can Gritstone bio stock reach $1?
GRTS's average twelve months analyst stock price target of $4.67 supports the claim that Gritstone bio can reach $1 in the near future.
What are Gritstone bio's analysts' financial forecasts?
Gritstone bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $9.69M (high $10.49M, low $8.9M), average EBITDA is $-9.694M (high $-8.895M, low $-10.49M), average net income is $-140M (high $-133M, low $-146M), average SG&A $56.91M (high $61.58M, low $52.22M), and average EPS is $-0.976 (high $-0.926, low $-1.016). GRTS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.5M (high $3.5M, low $3.5M), average EBITDA is $-3.5M (high $-3.5M, low $-3.5M), average net income is $-115M (high $-115M, low $-115M), average SG&A $20.55M (high $20.55M, low $20.55M), and average EPS is $-0.805 (high $-0.805, low $-0.805).
Did the GRTS's actual financial results beat the analysts' financial forecasts?
Based on Gritstone bio's last annual report (Dec 2023), the company's revenue was $16.34M, beating the average analysts forecast of $12.68M by 28.87%. Apple's EBITDA was $-140M, beating the average prediction of $-12.682M by 1000.92%. The company's net income was $-138M, missing the average estimation of $-195M by -28.92%. Apple's SG&A was $28.78M, missing the average forecast of $74.45M by -61.34%. Lastly, the company's EPS was $-0.0012, missing the average prediction of $-1.36 by -99.91%. In terms of the last quarterly report (Dec 2023), Gritstone bio's revenue was $13.84M, beating the average analysts' forecast of $5.11M by 170.88%. The company's EBITDA was $-40.24M, beating the average prediction of $-5.108M by 687.76%. Gritstone bio's net income was $-30.808M, missing the average estimation of $-46.881M by -34.28%. The company's SG&A was $7.92M, missing the average forecast of $29.99M by -73.60%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.327 by -99.91%